NCT00093964 2019-04-16
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
EMD Serono
Phase 2 Completed
Clinical Trials
9 trialsNCT00679354 2018-08-01
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00112866 2017-06-14
Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00813943 2017-01-30
CORE
EMD Serono
Phase 2 Completed
NCT00842712 2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00121238 2016-04-28
Cilengitide in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00085254 2016-02-25
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00689221 2014-11-04
CENTRIC
EMD Serono
Phase 3 Completed
NCT00705016 2014-04-30
ADVANTAGE
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed